The Role of Hypoxia in Ischemic Chronic Kidney Disease.
Textor SC, Lerman LO.
Semin Nephrol. 2019 Nov;39(6):589-598. doi: 10.1016/j.semnephrol.2019.10.008.
Nanomedicine in kidney disease.
Bishop B, Sharma S, Scott EA.
Curr Opin Nephrol Hypertens. 2023 Jul 1;32(4):366-376. doi: 10.1097/MNH.0000000000000897. Epub 2023 May 11.
Chronic kidney disease exacerbates ischemic limb myopathy in mice via altered mitochondrial energetics.
Berru FN, Gray SE, Thome T, Kumar RA, Salyers ZR, Coleman M, Dennis Le, O'Malley K, Ferreira LF, Berceli SA, Scali ST, Ryan TE.
Sci Rep. 2019 Oct 29;9(1):15547. doi: 10.1038/s41598-019-52107-7.
[Ischemic kidney disease].
Mustonen J, Wirta O.
Duodecim. 2006;122(2):208-14.
Concise review: mesenchymal stem cell treatment for ischemic kidney disease.
Zhu XY, Lerman A, Lerman LO.
Stem Cells. 2013 Sep;31(9):1731-6. doi: 10.1002/stem.1449.
Role of T cells in ischemic acute kidney injury and repair.
Lee K, Jang HR.
Korean J Intern Med. 2022 May;37(3):534-550. doi: 10.3904/kjim.2021.526. Epub 2022 Apr 28.
Atherosclerotic ischemic renal disease.
Greco BA, Breyer JA.
Am J Kidney Dis. 1997 Feb;29(2):167-87. doi: 10.1016/s0272-6386(97)90027-5.
Hypoxia and chronic kidney disease: Possible mechanisms, therapeutic targets, and relevance to cats.
Spencer S, Wheeler-Jones C, Elliott J.
Vet J. 2021 Aug;274:105714. doi: 10.1016/j.tvjl.2021.105714. Epub 2021 Jul 9.
Epigenetic changes mediating transition to chronic kidney disease: Hypoxic memory.
Tanaka T.
Acta Physiol (Oxf). 2018 Apr;222(4):e13023. doi: 10.1111/apha.13023. Epub 2018 Jan 15.
Cardiovascular disease in chronic kidney disease in 2015.
Sud M, Naimark DM.
Curr Opin Nephrol Hypertens. 2016 May;25(3):203-7. doi: 10.1097/MNH.0000000000000213.
